My research interest examines the mechanisms (such as inflammation, mitochondrial dysfunction, decreased nitric oxide bioavailability, and increase oxidative stress) of cerebrovascular dysfunction and cardiovascular disease in women (during pregnancy and postpartum) with hypertensive pregnancy complications, such as preeclampsia, and their offspring.
Preeclampsia, hypertension during pregnancy, not only affects the mother’s short-term (during pregnancy) and long-term (post-partum) health, but also the health of the neonates into adulthood. Two important factors that are associated with PE are Interleukin 17(IL-17) and the angiotensin II type 1 receptor agonistic autoantibodies (AT1-AA). My current research endeavor is to determine if blockade or interference with IL-17 and/or AT1-AAs during preeclampsia can improve maternal and fetal outcomes during pregnancy and later in life. My research areas of expertise include and are not limited to hypertension, women’s health, pregnancy, preeclampsia, and fetal programming.